Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Tuesday

Edwards Lifesciences (NYSE:EW) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $1.5425 billion for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 5:00 PM ET.

Edwards Lifesciences Trading Up 0.8%

EW opened at $78.71 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.68 billion, a price-to-earnings ratio of 33.93, a PEG ratio of 3.03 and a beta of 0.94. Edwards Lifesciences has a 12 month low of $65.94 and a 12 month high of $87.89. The stock has a fifty day moving average price of $84.15 and a 200-day moving average price of $81.13.

Wall Street Analyst Weigh In

Several research firms have commented on EW. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. The Goldman Sachs Group reiterated a “buy” rating and set a $108.00 price objective on shares of Edwards Lifesciences in a research note on Friday, January 9th. Barclays restated an “overweight” rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $96.77.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the transaction, the vice president owned 31,870 shares of the company’s stock, valued at $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently modified their holdings of EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Viking Global Investors LP acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $238,688,000. AQR Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 114.5% during the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after buying an additional 1,111,139 shares in the last quarter. Man Group plc raised its position in shares of Edwards Lifesciences by 73.9% in the second quarter. Man Group plc now owns 1,653,939 shares of the medical research company’s stock valued at $129,355,000 after buying an additional 702,712 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Edwards Lifesciences by 92.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 873,817 shares of the medical research company’s stock valued at $68,341,000 after buying an additional 420,551 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.